AMN

Current Thesis

AMN is the largest US healthcare-staffing firm (travel nurse, locum tenens, allied, language services) working through a multi-year post-COVID normalization. The stock fell from a ~$120 COVID-staffing peak (2022) to the mid-$20s as bill rates and volumes deflated. Q1 print (2026-05-07) showed an optical EPS beat ($2.10 adj vs $1.62 est) but the forward signal is soft: Q2 revenue guide of $620–635M came in BELOW the $634.9M consensus, and the sell-side stayed overwhelmingly Neutral (UBS Neutral PT→$32 on 5/13; Baird Neutral PT→$26 on 5/11). This is a cyclical-trough / value tape, not an accelerating narrative. For the narrative-momentum playbook it is a SKIP-quality, DORMANT name — no velocity, no fresh catalyst, no theme acceleration.

Bull Case

• Trough-is-in cyclical bottoming. Q1 2026 EPS $2.10 beat consensus $1.62 by 30% (reported 2026-05-07) — cost discipline is showing through even with revenue compressed. If staffing demand stabilizes, this is the kind of beaten-down cyclical that re-rates off a base.
• Sell-side targets drifting UP, not down. UBS raised PT to $32 (2026-05-13); BMO reiterated Outperform PT→$26 and Baird PT→$26 (both 2026-05-11). Targets nudging higher = downgrade cycle may be exhausting.
• Secular demand floor. Structural US nursing shortage and aging-demographics labor gap give a long-run demand backstop below the cyclical noise — a reason it can base rather than zero out.

Bear Case

• Forward guide is DECELERATING. Q2 guide $620–635M midpoint sits under the $634.9M Street estimate (2026-05-07) — the optical EPS beat masks a top line still grinding lower. Momentum books do not buy names guiding revenue down into consensus.
• Mostly Neutral coverage = no narrative. UBS and Baird both Neutral; the rating tape says "fairly valued, no edge." There is no upgrade cluster, no acceleration, nothing the sell-side is racing to catch up to.
• Value-trap structure. Cheap multiple on a rolled-over, multi-year downtrend from [entry redacted] → mid-$20s is exactly the setup the playbook flags as a value trap, not an entry. Cheapness without a price/volume inflection is not a thesis.
• Data flag: the Benzinga feed shows Q1 "Sales $1.378B" — inconsistent with a $620–635M Q2 guide and AMN's ~$650–700M quarterly run-rate; treat that figure as a feed error and anchor on the Q2 guide as the true trajectory.

Setup & Price Structure

• Exact intraday tick not in context. Triangulating from analyst PTs ($26 BMO/Baird → $32 UBS) and the May post-earnings reaction, the stock is in the mid-$20s, basing after a brutal 2022→2025 secular downtrend.
• Note the disagreement: UBS Neutral carries a HIGHER target ($32) than BMO's Outperform ($26) — a sign the name is range-bound and contested, not trending. No clean higher-low breakout structure that a momentum entry requires.
• This is a falling-knife-turned-base, NOT an ACCELERATING setup. No 20-EMA reclaim narrative, no cluster of peers breaking out. Stretched-above-MA risk is the opposite problem here — it's a flat, dead tape.

Catalyst Calendar (next 30 days)

• No binary catalyst inside the 30-day window (through ~2026-07-04).
• Next earnings: Q2 2026, ~early August 2026 (est.) — outside the window; Q1 was reported 2026-05-07, so the next print is ~3 months out. Do not probe into the blackout.
• No FDA/PDUFA, no M&A clock, no scheduled product catalyst. Possible summer healthcare-services conference appearances, but none is a needle-mover.

What Would Change Our Mind

• Flip bullish (real long): weekly close back above ~$32 (UBS PT / prior resistance) on expanding volume, ALONGSIDE evidence travel-nurse bill rates are inflecting higher (sequential revenue guide back above consensus). That converts the trough thesis into momentum.
• Confirm avoid / kill any probe: weekly close below ~[entry redacted] (under the May post-earnings base) — reconfirms the secular staffing-rate downtrend and resumes lower lows.
• A guidance cut on the August print, or a fresh wave of Street downgrades, ends the "trough-is-in" story entirely.

Correlation Notes

• Direct peer: Cross Country Healthcare (CCRN) — same travel-nurse / bill-rate cycle; watch it as the cleaner sector tell.
• Adjacent: managed care (UNH, HUM, CNC) under the "health-managed-care" theme tag, though AMN's real driver is hospital labor budgets, not MLR.
• Demand proxy: hospital operators (HCA, THC, UHS) — their staffing budgets and patient volumes set AMN's bill-rate environment.
• Inverse-ish: AMN demand spikes on COVID/flu surges (more crisis staffing = higher rates); a calm public-health backdrop is a revenue headwind.

Bottom Line

DORMANT / SKIP for the momentum book. LOW conviction on a fresh entry. Revisit only on a >$32 weekly breakout with bill-rate inflection, or as a small cyclical-trough probe if it holds the [entry redacted] base — never as a momentum buy at current structure.